Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256310 | 0.98 | HPGD (0.59) | HPGDTSHRALDH1A1NPSR1KMT2A | |
| SCHEMBL4243617 | 0.95 | HTT (0.58) | HPGDTSHRALDH1A1NPSR1KMT2A | |
| SCHEMBL1447805 | 0.87 | POLB (0.68) | HPGDTSHRALDH1A1KMT2ANPC1 | |
| SCHEMBL19086436 | 0.86 | HTT (0.47) | HPGDTSHRALDH1A1NPSR1KMT2A | |
| SCHEMBL1447243 | 0.86 | POLB (0.57) | HPGDTSHRALDH1A1NPSR1KMT2A | |
| SCHEMBL1447782 | 0.86 | HPGD (0.50) | HPGDKMT2AMEN1GAARAB9A | |
| SCHEMBL21189714 | 0.85 | HPGD (0.58) | HPGDTSHRALDH1A1NPSR1KMT2A | |
| SCHEMBL1085344 | 0.84 | L3MBTL3 (0.72) | — | |
| SCHEMBL19869975 | 0.84 | RXFP1 (0.48) | HPGDTSHRHTT | |
| SCHEMBL970089 | 0.84 | HPGD (0.55) | HPGDKMT2AGAARAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-8163727-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| CN-101048369-B | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB | 2010-09-08 | — | — | CN | disclosed |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7737135-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-1784388-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | EP | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| CN-101048369-A | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| EP-1784388-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021759-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | HPGD 751/4885TSHR 1185/4885ALDH1A1 42/4885 |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | HPGD 751/4885TSHR 1185/4885ALDH1A1 42/4885 |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | HPGD 751/4885TSHR 1185/4885ALDH1A1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.